FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1489-1491 April 8, 2004 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In June 2003, the Medicine and Healthcare Products Regulatory Agency of the British Department of Health warned physicians to avoid the off-label use of paroxetine, a selective serotonin-reuptake inhibitor (SSRI) antidepressant, for the treatment of depression in children (18 years of age or younger). This action was taken in response to concern about a possible association between SSRIs and suicidal behavior, which includes a broad range of symptoms ranging from fleeting thoughts of self-harm to attempted suicide. Proprietary data examined by the United Kingdom regulatory agency showed a slight increase in suicidal behavior among patients who were randomly assigned to . . . [Full Text of this Article]

Source Information

From the National Institute of Mental Health, Bethesda, Md.

This article has been cited by other articles:

• The TADS Team, (2007). The Treatment for Adolescents With Depression Study (TADS): Long-term Effectiveness and Safety Outcomes. Arch Gen Psychiatry 64: 1132-1143 [Abstract] [Full Text]  
• Juurlink, D. N., Mamdani, M. M., Kopp, A., Redelmeier, D. A. (2006). The Risk of Suicide With Selective Serotonin Reuptake Inhibitors in the Elderly. Am. J. Psychiatry 163: 813-821 [Abstract] [Full Text]  
• Patel, N. C, Crismon, M L., Shafer, A. (2006). Diagnoses and Antipsychotic Treatment Among Youths in a Public Mental Health System. The Annals of Pharmacotherapy 40: 205-211 [Abstract] [Full Text]  
• Simon, G. E., Savarino, J., Operskalski, B., Wang, P. S. (2006). Suicide Risk During Antidepressant Treatment. Am. J. Psychiatry 163: 41-47 [Abstract] [Full Text]  
• Sewitch, M. J., Blais, R., Rahme, E., Bexton, B., Galarneau, S. (2005). Pharmacologic Response to Depressive Disorders Among Adolescents. Psychiatr. Serv. 56: 1089-1097 [Abstract] [Full Text]  
• Caballero, J., Nahata, M. C. (2005). Selective serotonin-reuptake inhibitors and suicidal ideation and behavior in children. Am J Health Syst Pharm 62: 864-867 [Full Text]  
• Warden, S. J., Robling, A. G., Sanders, M. S., Bliziotes, M. M., Turner, C. H. (2005). Inhibition of the Serotonin (5-Hydroxytryptamine) Transporter Reduces Bone Accrual during Growth. Endocrinology 146: 685-693 [Abstract] [Full Text]  
• Steer, C R (2005). Managing attention deficit/hyperactivity disorder: unmet needs and future directions. Arch. Dis. Child. 90: i19-i25 [Abstract] [Full Text]  
• Asarnow, J. R., Jaycox, L. H., Duan, N., LaBorde, A. P., Rea, M. M., Murray, P., Anderson, M., Landon, C., Tang, L., Wells, K. B. (2005). Effectiveness of a Quality Improvement Intervention for Adolescent Depression in Primary Care Clinics: A Randomized Controlled Trial. JAMA 293: 311-319 [Abstract] [Full Text]  
• The Pediatric OCD Treatment Study (POTS) Team, (2004). Cognitive-Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial. JAMA 292: 1969-1976 [Abstract] [Full Text]  
• Finley, P. R (2004). Antidepressants, Suicide, and the FDA: A Loose Association. The Annals of Pharmacotherapy 38: 1739-1742 [Full Text]  
• Treatment for Adolescents With Depression Study T, (2004). Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial. JAMA 292: 807-820 [Abstract] [Full Text]  
• Glass, R. M. (2004). Treatment of Adolescents With Major Depression: Contributions of a Major Trial. JAMA 292: 861-863 [Full Text]  
• Brent, D. A. (2004). The Rewards of Reducing Risk. Arch Pediatr Adolesc Med 158: 824-825 [Full Text]